Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2007

View Archived Issues

Preclinical data from AHA meeting on cardiac ischemia therapies

Adalimumab lowers uveitis flare rate in ankylosing spondylitis patients

Further RAPID study data show efficacy of certolizumab in rheumatoid arthritis

Neuropathic pain reduced with transdermal fentanyl

NovImmune develops novel mAbs with potential use in septic shock / News in Context

Recent patents divulge new therapeutic agents for cancer

Selective antagonists of the SST5 receptor identified at Roche

Recent Gyeongsang National University patent imparts new treatment for skin hyperpigmentation

FDA approves Bionomics' IND application for anticancer compound BNC-105

Research on gene-based reprogramming of human stem cells shows positive results for c-myc

Ardana reports positive results from clinical trial of its testosterone cream

Diamyd enters agreement with National Institutes of Health for trial of Diamyd

Chi-Med to initiate phase IIb trial of HMPL-004 for ulcerative colitis

The A3AR as putative target of autoimmune disease therapy

New treatment options for psychotic, depressive and anxiety disorders reported in recent patents

Schering-Plough reports third quarter 2007 results

Gilead announces third quarter 2007 results

Bristol-Myers Squibb and Pierre Fabre terminate license agreement for vinflunine

ALK-Abello reports positive results from GT-12 phase III clinical study of Grazax in children

Medicago reports further positive results from preclinical study of H5N1 avian influenza vaccine

FDA approves Wyeth Pharmaceuticals' Protonix for delayed-release oral suspension

GW Pharmaceuticals and Otsuka initiate phase II/III clinical trial of Sativex for cancer pain

FDA accepts for filing Schering-Plough's NDA for asenapine for schizophrenia

Medivir presents an update on clinical programs for Lipsovir and MIV-701

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...